Fencamfamine

Jump to: navigation, search
Fencamfamine
Fencamfamine Wiki Str.png
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H21N
Molar mass215.34 g·mol−1

WikiDoc Resources for Fencamfamine

Articles

Most recent articles on Fencamfamine

Most cited articles on Fencamfamine

Review articles on Fencamfamine

Articles on Fencamfamine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fencamfamine

Images of Fencamfamine

Photos of Fencamfamine

Podcasts & MP3s on Fencamfamine

Videos on Fencamfamine

Evidence Based Medicine

Cochrane Collaboration on Fencamfamine

Bandolier on Fencamfamine

TRIP on Fencamfamine

Clinical Trials

Ongoing Trials on Fencamfamine at Clinical Trials.gov

Trial results on Fencamfamine

Clinical Trials on Fencamfamine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fencamfamine

NICE Guidance on Fencamfamine

NHS PRODIGY Guidance

FDA on Fencamfamine

CDC on Fencamfamine

Books

Books on Fencamfamine

News

Fencamfamine in the news

Be alerted to news on Fencamfamine

News trends on Fencamfamine

Commentary

Blogs on Fencamfamine

Definitions

Definitions of Fencamfamine

Patient Resources / Community

Patient resources on Fencamfamine

Discussion groups on Fencamfamine

Patient Handouts on Fencamfamine

Directions to Hospitals Treating Fencamfamine

Risk calculators and risk factors for Fencamfamine

Healthcare Provider Resources

Symptoms of Fencamfamine

Causes & Risk Factors for Fencamfamine

Diagnostic studies for Fencamfamine

Treatment of Fencamfamine

Continuing Medical Education (CME)

CME Programs on Fencamfamine

International

Fencamfamine en Espanol

Fencamfamine en Francais

Business

Fencamfamine in the Marketplace

Patents on Fencamfamine

Experimental / Informatics

List of terms related to Fencamfamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Reactivan is still rarely used for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases.[1]

Legal Status: Schedule IV (USA)

Pharmacology

Fencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is 10x less potent than dexamphetamine at producing this effect. The main mechanism of action is instead inhibition of dopamine reuptake, more similar to that of methylphenidate. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes and so is somewhat safer.[2] Some experiments also suggest a role for opioid receptors in the activity of fencamfamine, as low doses can cause paradoxical sedation, and some effects of the drug are blocked by naloxone.[3]

Side effects

Side effects include: dry mouth, loss of appetite, restlessness and tremor.

Contraindications

Contraindications: should not be used in patients with heart disease, angina, glaucoma, thyrotoxicosis or in patients being treated with monoamine oxidase inhibitors.

References

  1. http://home.intekom.com/pharm/merckp/reactivn.html
  2. Seyfried CA. Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochemical Pharmacology. 1983 Aug 1;32(15):2329-31.
  3. Planeta Cda S, Aizenstein ML, DeLucia R. Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors. Pharmacology, Biochemistry and Behavior. 1995 Jan;50(1):35-40.

Linked-in.jpg